Walgreens Boots Alliance, Inc. (WBA) - NASDAQ
  • Thu, Jan. 14, 2:51 AM
    • WebMD (NASDAQ:WBMD), the U.S. online health information publisher, is exploring the possible sale of all or part of its business, FT reports.
    • The company is said to be in talks with Walgreens Boots Alliance (NASDAQ:WBA) and UnitedHealth (NYSE:UNH), among other potential buyers.
    • Since the start of the year WebMD shares have risen 10%, giving the company a market value of close to $2B.
    • Update: Shares are up 6% premarket on increased volume.
    | Thu, Jan. 14, 2:51 AM
  • Thu, Jan. 7, 7:52 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports comparable-store sales rose 5.8% in FQ1.
    • Retail pharmacy USA division sales rose 4.2% to $20.37B.
    • Pharmacy sales rose 6.7% on a 4.7% gain in prescription count for the quarter.
    • Adjusted gross margin rate fell 130 bps to 26%.
    • Adjusted gross margin rates by segment: Retail Pharmacy USA 27%, Retail Pharmacy International 42.6%, Pharmaceutical Worldwide 9.6%.
    • Adjusted SG&A expense rate -210 bps to 20.1%.
    • Adjusted operating margin rate increased 20 bps to 5.9%.
    • FY2016 Guidance: Adjusted EPS: $4.30 to $4.55.
    • WBA -0.19% premarket.
    | Thu, Jan. 7, 7:52 AM
  • Thu, Jan. 7, 7:03 AM
    • Walgreens Boots (NASDAQ:WBA): FQ1 EPS of $1.03 beats by $0.07.
    • Revenue of $29.03B (+48.5% Y/Y) misses by $210M.
    | Thu, Jan. 7, 7:03 AM
  • Wed, Jan. 6, 5:30 PM
    | Wed, Jan. 6, 5:30 PM | 1 Comment
  • Dec. 22, 2015, 3:49 AM
    • Buried in the details of a new 20-year distribution agreement between Valeant Pharmaceuticals (NYSE:VRX) and Walgreens Boots Alliance (NASDAQ:WBA) is a $150M financial hit to Valeant that underscores the unusual nature of the deal (which will see the firm buy back its own drugs from Walgreens and then resell them on consignment to the pharmacy).
    • The pact will help Valeant replace a controversial mail-order pharmacy, Philidor, which had close ties to the drug company and used aggressive tactics to win insurance payments.
    • Previously: Valeant inks fulfillment deal with Walgreens; shares up 8% premarket (Dec. 15 2015)
    | Dec. 22, 2015, 3:49 AM | 13 Comments
  • Dec. 15, 2015, 9:00 AM
    • Valeant Pharmaceuticals (NYSE:VRX) enters into a 20-year fulfillment agreement with Walgreens (NASDAQ:WBA) under which consumers can conveniently access Valeant's dermatology and ophthalmology products and its over-the-counter portfolio from more than 8,000 Walgreens U.S.-based pharmacies. In addition, it will reduce the wholesale list prices of its branded prescription-based dermatology and ophthalmology offerings by 10%, to be phased in over the next six to nine months. The agreement takes effect in Q1.
    • The companies have also inked a separate deal under which Valeant will distribute more than 30 branded products, where generics are available, through Walgreens at generic prices. The discounted pricing, ranging from 5% to 95%, will be available to patients in H2 2016. Eligible products represent dermatology, ophthalmology, gastrointestinal and neurology/other and include Aldara, Tiazac and Glumetza.
    • Valeant expects the price discounts to provide up to $600M in annual savings to the U.S. healthcare system, when fully implemented.
    • The company intends to extend this distribution model to additional independent retail pharmacies.
    | Dec. 15, 2015, 9:00 AM | 48 Comments
  • Nov. 11, 2015, 8:59 AM
    • Grocer Safeway's (NYSE:SWY) much-ballyhooed initiative to build medical clinics in its supermarkets in which they would offer blood tests by diagnostics upstart Theranos is apparently DOA. The clinics, numbering about 800 and costing $350M to set up, are now used primarily for delivering flu shots and travel-related vaccines after Theranos kept delaying the roll-out of its tests and backed away from its plan to place its analyzers in each clinic, opting instead to ship the blood samples to a central location for testing.
    • Safeway's interest in providing wellness services was driven by then-CEO Steven Burd who retired in 2013. The plan was to establish upscale clinics in stores that would house Theranos' analyzers which would provide rapid test results from finger-stick samples.
    • The initial phase of the project ran into difficultly when comparative blood testing was performed at the headquarters clinic. Both finger stick and venous samples were taken from employee volunteers which gave them the impression that the finger stick samples were a work in progress. Not helping matters was a male volunteer who received a PSA result that indicated the presence of prostate cancer but came back normal when retested by another lab.
    • The project has been dormant for more than a year. CEO Elizabeth Holmes has ceased interacting with Safeway executives and has delegated the management of the relationship to President and COO Sunny Balwani.
    • Theranos' deal with Walgreens Boots Alliance (NASDAQ:WBA) to establish blood-testing centers in its stores is on hold (41 current locations) until questions about its technology are answered.
    • Previously: Walgreens halts openings of new Theranos centers (Oct. 24)
    • Previously: Theranos chief Holmes says technology sound (Oct. 21)
    | Nov. 11, 2015, 8:59 AM | 7 Comments
  • Nov. 2, 2015, 7:27 PM
    • Walgreens Boots Alliance (WBA +2.2%) says it would be willing to sell off up to 1,000 stores in order to wrap a buyout of Rite Aid (RAD +0.6%).
    • The company had said it had looked at antitrust concerns but hadn't put a number to what divestitures might be required.
    • One thousand of the stores would come to 8% of the combined companies' total footprint, though in a presentation filed with the SEC, Walgreens "believes the most likely outcome is divestments of less than half this number."
    • Walgreens said it expects the deal to be accretive during the first full year after closing, with synergies in excess of $1B, primarily from procurement, cost savings and operational synergies.
    • Previously: Regulatory concerns surround Walgreens, Rite Aid deal (Oct. 29 2015)
    | Nov. 2, 2015, 7:27 PM | 11 Comments
  • Oct. 29, 2015, 2:32 AM
    • Top antitrust lawmakers in the U.S. Senate are calling for close scrutiny of Walgreens Boots Alliance's (NASDAQ:WBA) plan to buy Rite Aid (NYSE:RAD), the latest healthcare consolidation following the rollout of the Affordable Care Act.
    • The deal would unite two of the three largest U.S. drugstore chains, the other being CVS Health (NYSE:CVS).
    • Walgreens Chief Executive Stefano Pessina said previously that the company had analyzed the antitrust aspect of the deal but did not speculate on the number of drugstores it might need to divest in order to win regulatory approval.
    • Previously: Walgreens buying Rite Aid for $17.2B ($9/share) (Oct. 27 2015)
    | Oct. 29, 2015, 2:32 AM | 30 Comments
  • Oct. 28, 2015, 10:43 AM
    • Execs with Walgreen Boots Alliance (NASDAQ:WBA) said the EnvisionRX business it will swallow up as part of the Rite Aid purchase will help it learn how to increase PBM synergies. EnvisionRX was acquired by Rite Aid earlier this year for $2B.
    • A very interesting question on how many stores will be divested or closed as part of the Rite Aid deal goes unanswered. Walgreens will have strategic and regulatory reasons to make some store changes.
    • What about tobacco? As Walgreens pushed deeper into pharmacy benefits and healthcare services the sale of tobacco appears to be a stickler. For now, Walgreens has no update.
    • Management also talked about some positive trends in the front end of its stores.
    • Investors are in a selling mood this morning on WBA, shares are down 8.4% on heavy volume. It's possible the EPS impact of pulling the buyback program could be factoring in.
    • Previously: Walgreens Boots beats by $0.07, beats on revenue (Oct. 28 2015)
    • Previously: Synergies start to kick in for Walgreens Boots Alliance (Oct. 28 2015)
    • Walgreens Boots Alliance earnings call webcast
    | Oct. 28, 2015, 10:43 AM | 16 Comments
  • Oct. 28, 2015, 7:45 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports total sales in comparable drugstores rose 6.4% in FQ4 off a 1.5% retail comp.
    • Pharmacy sales grew 8.2% on a 4.6% gain in prescription count for the quarter.
    • Adjusted gross margin rates (non-GAAP) by segment: Retail Pharmacy USA 26.3%, Retail Pharmacy International 42.6%, Pharmaceutical Worldwide 9.4%.
    • Total drugstore count -34 Y/Y to 8,173.
    • Combined synergy benefits for the full fiscal year came in at $799M.
    • Guidance: The company expects FY16 EPS of $4.25 to $4.55. The outlook reflects the suspension of the share repurchase program in order to finance the Rite Aid acquisition.
    • Previously: Walgreens Boots beats by $0.07, beats on revenue (Oct. 28 2015)
    • WBA +0.57% premarket to $95.70.
    | Oct. 28, 2015, 7:45 AM
  • Oct. 28, 2015, 7:04 AM
    • Walgreens Boots (NASDAQ:WBA): FQ4 EPS of $0.88 beats by $0.07.
    • Revenue of $28.52B (+49.6% Y/Y) beats by $70M.
    | Oct. 28, 2015, 7:04 AM | 3 Comments
  • Oct. 27, 2015, 5:30 PM
  • Oct. 27, 2015, 5:27 PM
    • Confirming media reports, Walgreens Boots (NASDAQ:WBA) announces it's buying fellow drugstore owner Rite Aid (NYSE:RAD) for $17.2B after factoring debt, or $9/share, in cash. The deal is expected to close in 2H16; Walgreen expects to eventually reap over $1B/year in synergies.
    • The price represents a 48% premium to Rite Aid's Monday close, and is also $0.33 above Rite Aid's Tuesday close of $8.67. Nonetheless, Rite Aid is down 6.3% after hours to $8.12, as a healthy M&A arb spread opens. Walgreens is up 0.9% to $96.00, after rising 6.4% in regular trading.
    • Following the deal's closing, Rite Aid is expected to initially continue operating under its existing brand. However, decisions "will be made over time regarding the integration of the two companies, ultimately creating a fully harmonized portfolio of stores and infrastructure."
    • Walgreens plans to finance the deal with both debt and existing cash. It's expected to be accretive in its first year after closing.
    | Oct. 27, 2015, 5:27 PM | 90 Comments
  • Oct. 27, 2015, 12:45 PM
    • Rite Aid (NYSE:RAD) shares have reopened for trading with a 39.7% burst on a Dow Jones report that Walgreens Boots Alliance (NASDAQ:WBA) is close to a deal to acquire the firm.
    • The deal -- which would link the No. 2 and No. 3 drugstore chains in the U.S. -- is expected to come tomorrow, sources tell Dow Jones.
    • Typical takeover premiums could value Rite Aid at close to $10B in the purchase, vs. its pre-news $6B market cap.
    • In its last quarter, Rite Aid’s profit sank due to cost of integrating recently acquired Envision Pharmaceutical Services, the WSJ notes.
    • Updated 12:55 p.m.: Walgreens shares have spiked on the news as well, up 4.3%.
    • Related: Riding The Rite Aid Roller Coaster (Oct. 27 2015)
    | Oct. 27, 2015, 12:45 PM | 44 Comments
  • Oct. 24, 2015, 7:50 AM
    • “We’re trying to figure out where we are and what we do going forward," a Walgreens Boots Alliance (NASDAQ:WBA) source tells the WSJ. "We need to understand the truth."
    • The drugstore chain has "no concrete plans at this stage" to expand its partnership with Theranos beyond the 41 stores in Arizona and California which already include Theranos "wellness centers," reports the Journal. That partnership also includes an equity stake in the startup.
    • Walgreens made the move after meeting late this week with top brass at Theranos, including CEO Elizabeth Holmes. Said meeting came about after stories questioning the viability of the startup's technology. Walgreens was also unaware of the FDA's surprise inspection of Theranos facilities in August and September, according to sources.
    • Previously: Theranos chief Holmes says technology sound (Oct. 21)
    • Related tickers: Abbot Labs (NYSE:ABT), Quest Diagnostics (NYSE:DGX), Lab Corp. (NYSE:LH), Roche Holding (OTCQX:RHHBY)
    | Oct. 24, 2015, 7:50 AM | 21 Comments
Company Description
Walgreens Boots Alliance, Inc. provides drug store services. It operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment engages in pharmacy-led health and beauty retail businesses, which sells its... More
Sector: Services
Industry: Drug Stores
Country: United States